[go: up one dir, main page]

Nunchai et al., 2020 - Google Patents

Optimal cutoff of mean corpuscular volume (MCV) for screening of alpha‐thalassemia 1 trait

Nunchai et al., 2020

View PDF
Document ID
1559847394709094238
Author
Nunchai C
Sirichotiyakul S
Tongsong T
Publication year
Publication venue
Journal of Obstetrics and Gynaecology Research

External Links

Snippet

Aim To identify the optimal cutoff of mean corpuscular volume (MCV) for screening of alpha‐ thalassemia 1 trait. Methods The database of pregnant women who attended antenatal care clinic at Department of Obstetrics and Gynecology, Chiang Mai University during January …
Continue reading at w1.med.cmu.ac.th (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
    • G06Q40/02—Banking, e.g. interest calculation, credit approval, mortgages, home banking or on-line banking
    • G06Q40/025—Credit processing or loan processing, e.g. risk analysis for mortgages
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/36—Computer-assisted acquisition of medical data, e.g. computerised clinical trials or questionnaires
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G06F19/34—Computer-assisted medical diagnosis or treatment, e.g. computerised prescription or delivery of medication or diets, computerised local control of medical devices, medical expert systems or telemedicine
    • G06F19/345—Medical expert systems, neural networks or other automated diagnosis
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/30—Information retrieval; Database structures therefor; File system structures therefor
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/10—Office automation, e.g. computer aided management of electronic mail or groupware; Time management, e.g. calendars, reminders, meetings or time accounting

Similar Documents

Publication Publication Date Title
Canick et al. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies
Gil et al. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell‐free DNA test contingent on results from first‐trimester combined test
Creighton et al. Predictive, pre‐natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000
Lamb et al. How should proteinuria be detected and measured?
Bifulco et al. Childhood adversity, parental vulnerability and disorder: examining inter‐generational transmission of risk
Hoppe Prenatal and newborn screening for hemoglobinopathies
Alldred et al. First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening
Murphy et al. The use of precision diagnostics for monogenic diabetes: a systematic review and expert opinion
Sirichotiyakul et al. Sensitivity and specificity of mean corpuscular volume testing for screening for α‐thalassemia‐1 and β‐thalassemia traits
Rafalko et al. Impact of mosaicism ratio on positive predictive value of cfDNA screening
Paintsil et al. Analysis of haematological parameters as predictors of malaria infection using a logistic regression model: A case study of a hospital in the Ashanti Region of Ghana
Tynan et al. Application of risk score analysis to low‐coverage whole genome sequencing data for the noninvasive detection of trisomy 21, trisomy 18, and trisomy 13
Muzzey et al. Noninvasive prenatal screening for patients with high body mass index: evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk
Nunchai et al. Optimal cutoff of mean corpuscular volume (MCV) for screening of alpha‐thalassemia 1 trait
Saadi et al. The association between aspartate aminotransferase (AST) to platelets (PLT) ratio (APRI) and the development of intrahepatic cholestasis in pregnancy and other related complications
Jiang et al. Evaluation of intervention strategy of thalassemia for couples of childbearing ages in Centre of Southern China
Caldwell et al. Not all low fetal fraction cell‐free DNA screening failures are at increased risk for aneuploidy
Dreux et al. Biochemical analysis of ascites fluid as an aid to etiological diagnosis: a series of 100 cases of nonimmune fetal ascites
Penman et al. Epistasis and the sensitivity of phenotypic screens for beta thalassaemia
Brooke et al. Rapid (partial) prescreening of cervical smears: the quality control method of choice?
Turriff et al. Patients' perspectives on prenatal screening results that suggest maternal cancer: A qualitative analysis
Chen et al. Pregnancy from mosaic embryo transfer: genetic counseling considerations
Bunkall et al. Evaluation of an immunochromatographic strip test for alpha‐thalassaemia screening
Sirichotiyakul et al. A comparison of the accuracy of the corpuscular fragility and mean corpuscular volume tests for the alpha‐thalassemia 1 and beta‐thalassemia traits
US5798267A (en) Method for determining alcohol consumption rates